Matthew Sanders

Matthew Sanders is vice-president, head of Global Drug Substance at GSK, Rixensart, Belgium.

Articles

Ipopba/Stock.adobe.com – Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.

Introducing a New Concept for Value-Driven Acceleration in Biopharma Development

Matthew Sanders;Roland Mainil;Wael Chahim

October 2nd 2022

Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 11th 2024 | Updated: September 18th 2024

CPHI Pharma Award Finalists Announced for 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Published: March 27th 2024 | Updated: June 28th 2024

AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product

Published: October 28th 2024 | Updated: November 21st 2024

Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development

Published: November 15th 2024 | Updated: November 21st 2024

Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs

Published: October 28th 2024 | Updated: November 21st 2024

Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems

Published: October 22nd 2024 | Updated: November 21st 2024

Optimizing cGMP Facility Design Space with a Hybrid Approach

About Us

Advertise

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777